Department of Global Public Health and Primary Care

Mahdi Fallah – new professor in epidemiology at IGS

Mahdi Fallah started his position as professor in epidemiology at IGS in May 2021. Fallah is a physician and has received his PhD in cancer epidemiology from the University of Tampere (Finland) in 2007.

Portrait photo of Mahdi Fallah
Mahdi Fallah

Main content

Since 2009, he has been working at the German Cancer Research Center (DKFZ) in Heidelberg, Germany, and has been the Group Leader of the Risk Adapted Cancer Prevention Group since 2015. Fallah is a cancer epidemiologist and has a long-term experience in working with large Nordic registry-based studies.

His main research foci are personalized cancer prevention and familial cancer risk. With a risk-adapted approach to cancer prevention, he aims to further improve personalized cancer screening for several cancers, such as breast cancer (http://doi.org/10.1001/jamaoncol.2020.0292) and  colorectal cancer (https://doi.org/10.1053/j.gastro.2020.03.063), especially in those with family history of cancer or personal history of common diseases like diabetes (https://doi.org/10.1371/journal.pmed.1003431).

Together with colleagues, he has recently published the article "Risk of prostate cancer in relatives of prostate cancer patients in Sweden: A nationwide cohort study" in PLOS Medicine (https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003616).

In conjunction with the publishing, the following press release was sent out: “When should screening start for men with a family history of prostate cancer?” (https://www.eurekalert.org/pub_releases/2021-06/p-wss052721.php) and was covered in the news worldwide (https://plos.altmetric.com/details/106836091/news ).

He and his team believe that “the one-size-fits-all policy in medicine belongs to the past; more and more risk-adapted approaches are needed instead to optimize use of restricted resources in health care”. His intention is to fill this gap (a personalized approach in cancer screening) for various cancers, using long-standing high-quality large-scale register-based data, to provide robust evidence to support national and international screening guidelines.

We warmly welcome Professor Fallah to IGS.